. Distribution of aripiprazole once monthly (AOM) monotherapy and AOM/APpoly during the study. From AOM monotherapy to AOM/ antipsychotic polypharmacy (APpoly) n = 5, from AOM/APpolyo AOM monotherapy n = 2, Exact significance (2-tailed, p = 0.453), McNemar Test.
. The change of the Positive and Negative Syndrome Scale (PANSS) subscores during the study. For PANSS positive score, p = 0.065, p = 0.027, p = 0.023, and p = 0.015 between baseline to month 3, month 3 to month 6, month 6 to month 12, and baseline to month 12, respectively, Wilcoxon Signed Rank test; Time effect, df = 3, F = 3.624, p = 0.038, one way GLM; For PANSS negative score, p = 0.005, 0.001, 0.007, and 0.001 between baseline to month 3, month 3 to month 6, month 6 to month 12, and baseline to month 12, respectively, Wilcoxon Signed Rank test; Time effect, df = 3, F = 9.061, p = 0.001, one way GLM; For PANSS general score, p = 0.090, 0.012, 0.010, and 0.001 between baseline to month 3, month 3 to month 6, month 6 to month 12, and baseline to month 12, respectively, Wilcoxon Signed Rank test; Time effect, df = 3, F = 7.143, p = 0.003, one way GLM. Supplementary Fig. 3 . Differences in changes of scores between patients completed 12 months observation and non-completers. Tot, total score; pos, positive; neg, negative; gen, general; CGI-S, Clinical Global Impression-Severity; PANSS, The Positive and Negative Syndrome Scale; Mann-Whitney U test; p = 0.007, p = 0.053, p = 0.000, p = 0.616, p = 0.291, respectively from the left side in the figure (n = 12 vs. n = 6). Supplementary Fig. 4 . Differences in changes of scores between patients completed 6 months observation and less than 6 months observation. Tot, total score; pos, positive; neg, negative; gen, general; AOM, aripiprazole once monthly; CGI-S, Clinical Global Impression-Severity; PANSS, The Positive and Negative Syndrome Scale; Mann-Whitney U test; p = 0.078, p = 0.078, p = 0.157, p = 1.000, p = 0.837, respectively from the left side in the figure (n = 16 vs. n = 2). Supplementary Table 1 . Other psychotropics administration pattern during the study (n = 18)
Variable Value
Mood stabilizers immediate before AOM, yes 2 (11.1) Mood stabilizers at the first time of AOM (baseline), yes 2 (11.1) Mood stabilizers at month 3, yes 1 (5.6) Mood stabilizers at month 6, yes 1 (5.6) Mood stabilizers at month 12, yes 1 (5.6) Antiparkinsonian drugs immediate before AOM, yes 8 (44.4) Antiparkinsonian drugs at the first time of AOM (baseline), yes 7 (38.9) Antiparkinsonian drugs at month 3, yes 3 (16.7) Antiparkinsonian drugs at month 6, yes 2 (11.1) Antiparkinsonian drugs at month 12, yes 4 (22.2) Antianxiety drugs immediate before AOM 0.9 ± 1.0 Antianxiety drugs at the first time of AOM (baseline) 0.7 ± 0.8 Antianxiety drugs at month 3 0.7 ± 0.8 Antianxiety drugs at month 6 0.6 ± 0.8 Antianxiety drugs at month 12 0.4 ± 0.6
Values are presented as number (%) or mean ± standard deviation. AOM, aripiprazole once monthly.
